FDA grants Breakthrough Therapy status for a promising new drug targeting the rare and fatal Sanfilippo Syndrome Type B.
The strategic partnership for 6 gigawatts of GPU deployment challenges Nvidia's dominance and signals a new era in AI infrastructure.
The biotech firm secured its sixth approval for the ZORYVE franchise, expanding its dermatology treatment to children as young as two.
Despite a revenue beat, the semiconductor equipment supplier's net loss and missed earnings per share estimates sent shares tumbling in after-hours trading.
New trade measure seen as a significant tailwind for domestic transport and logistics companies, boosting sector stocks.
Taiwan Semiconductor hits a 52-week high while AMD and OpenAI announce a landmark chip deal, signaling sustained bullish momentum for chipmakers.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
Investors are closely watching the beverage giant's Q3 results on Monday for insights into the health of the alcoholic beverage market.